Merck is dropping a slate of experimental eye drugs from its partnership with NGM Bio, marking another dead end for their seven-year alliance.
The decision to pass over an option to pick up an anti-C3 antibody dubbed NGM621 comes two months after NGM reported that it flunked a Phase II...
